Opinion|Videos|August 21, 2024
ADCs in Breast Cancer: Mechanism of Action, and Components
Medical experts discuss the distinct mechanisms and components of different antibody-drug conjugates (ADCs), including the drug, antibody, and linker, and how these components contribute to the mechanisms of ADC-related toxicities.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the different mechanisms between these antibody-drug conjugates (ADCs), as well as the different components that make up these ADCs (ie, drug, antibody, linker)?
- Please briefly comment on how the different ADC components relate to the mechanism of some of the ADC-related toxicities.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5